Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Treatment Outcomes and Safety of Neoadjuvant Pembrolizumab-containing Therapy in Patients With Triple-negative Breast Cancer: Korean Nationwide Multicenter Study (Pembro-Real World)

NCT07828652 is registered in ClinicalTrials.gov with Yeon Hee Park as lead sponsor.

NCT NCT07828652
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07828652 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Treatment Outcomes and Safety of Neoadjuvant Pembrolizumab-containing Therapy in Patients With Triple-negative Breast Cancer: Korean Nationwide Multicenter Study (Pembro-Real World)
Lead sponsor
Yeon Hee Park
Phase
Observational
Overall status
Not yet recruiting
Start date
September 14, 2026
Completion date
December 31, 2027
Enrollment
2,000 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

tnbc - triple-negative breast cancer